|Security||UNIT / Uniti Group Inc. (20341J104)|
|President and CEO||Gunderman Kenny|
|Industry||Real Estate Investment Trusts|
|Institutional Shares||13,593,262 - 7.74%|
|Common Shares Outstanding||175,703,882 shares (as of 2018-03-31)|
|Institutional Value||$ 2,977,464,000 USD|
CSAL / Communications Sales & Leasing, Inc.|
Institutional Stock Ownership and Shareholders()
Uniti Group Inc. (NASDAQ:UNIT) has 15 institutional investors and shareholders that have
filed 13D/G or 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 13,593,262 shares.
Largest shareholders include
BlackRock Fund Advisors, BlackRock Institutional Trust Company, N.A., Toscafund Asset Management LLP, BlackRock Investment Management, LLC, Group One Trading, L.p., Group One Trading, L.p., PVG Asset Management, BlackRock Group LTD, Hbk Investments L P, and BlackRock Advisors LLC.
Uniti Group Inc. (NASDAQ:UNIT) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.
Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/unit"><img src="https://images.fintel.io/us-unit-so.png" alt="UNIT / Uniti Group Inc. Institutional Ownership"><a>
|PVG Asset Management||119,730||104,624||-12.62||3,460,197||2,658,495||-23.17|
|MetLife Securities, Inc||15,530||11,378||-26.74||488||290||-40.57|
|SIMPLEX TRADING, LLC||Call||843||462||-45.20||44||31||-29.55|
|BlackRock Advisors LLC||70,540||75,578||7.14||2,216||1,920||-13.36|
|Spot Trading L.L.C||Call||19,600||0||-100.00||498||0|
|BlackRock Group LTD||100,436||102,941||2.49||3,153||2,616||-17.03|
|GROUP ONE TRADING, L.P.||Call||28,800||324,000||1,025.00||512||5,265||928.32|
|STEADFAST ADVISORS LP||105,409||35,983||-65.86||3,311||914||-72.40|
|NEW YORK LIFE TRUST CO||989||0||-100.00||25||0||-100.00|
|MONROE BANK & TRUST/MI||918||0||-100.00||23||0||-100.00|
|EDMOND DE ROTHSCHILD (SUISSE) S.A.||13,731||431|
|MASON STREET ADVISORS, LLC||62,896||1,976|
|HBK INVESTMENTS L P||Call||100,000||100,000||0.00||1,779||1,625||-8.66|
|BlackRock Fund Advisors||5,780,081||5,888,335||1.87||181,552||149,623||-17.59|
|BlackRock Institutional Trust Company, N.A.||3,975,264||4,140,195||4.15||124,863||105,202||-15.75|
|Alpha Omega Wealth Management LLC||19||19||0.00||0||0|
|EverPoint Asset Management, LLC||216,000||0||-100.00||6,785||0||-100.00|
|GROUP ONE TRADING, L.P.||Put||108,000||255,100||136.20||1,921||4,145||115.77|
|CT Financial Advisors LLC||120||0||-100.00||3,049||0||-100.00|
|R&F Capital Advisors LP||19,896||0||-100.00||506||0|
|Kernodle & Katon Asset Management Group, LLC||44,086||0||-100.00||1,120||0||-100.00|
|JANUS CAPITAL MANAGEMENT LLC||239,200||0||-100.00||6,078||0||-100.00|
|Toscafund Asset Management LLP||1,850,000||2,675,000||44.59||29,286||43,735||49.34|
|Spot Trading L.L.C||Put||2,200||0||-100.00||56||0|
|BlackRock Investment Management, LLC||399,239||482,582||20.88||12,540||12,262||-2.22|
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Related News Stories
While WIN drama will continue to rule the short-term price action, UNIT's ability to execute their growth plan will be the key. (1-0)
Uniti Group's shares fell double-digits in Wednesday's trading session after downgrade from Citigroup analyst to a price target of $15.
The recent news cycle has Uniti Group (UNIT) slumping to recent lows. All it takes for a high-yielding REIT to slump is news of a big fund unloading shares and a negative call from an influential analyst. The dip caused by the sudden negative sentiment offers another opportunity here. (0-1)
CORR has proven that the revenue stream is reliable, even in periods of distress, as long as the assets are critical to the upstream operators. (15-0)
Long-time readers know that I have been following the Windstream Holdings (NASDAQ:WIN) vs. Aurelius Capital case closely. With the trial scheduled just a week and a half away, the end is in sight. The case will determine whether or not WIN is in default and whether or not the Uniti Group (NASDAQ:UNIT) spin-off amounted to a sale-leaseback that violated the indentures of WIN's bonds. (0-1)
as of ET